Passa al contenuto
Merck
  • Multiple micronutrient supplementation transiently ameliorates environmental enteropathy in Malawian children aged 12-35 months in a randomized controlled clinical trial.

Multiple micronutrient supplementation transiently ameliorates environmental enteropathy in Malawian children aged 12-35 months in a randomized controlled clinical trial.

The Journal of nutrition (2014-11-21)
Hannah E Smith, Kelsey N Ryan, Kevin B Stephenson, Claire Westcott, Chrissie Thakwalakwa, Ken Maleta, Jacqueline Y Cheng, J Thomas Brenna, Robert J Shulman, Indi Trehan, Mark J Manary
ABSTRACT

Environmental enteropathy (EE) is subclinical, diffuse villous atrophy characterized by T cell infiltration of the small intestinal mucosa associated with nutrient malabsorption and stunting. EE is assessed by the lactulose:mannitol (L:M) test, whereby nonmetabolized sugars are ingested and quantified in the urine. Multiple micronutrient (MN) deficiency morphologically mimics EE, and ω-3 (n-3) polyunsaturated fatty acids reduce mucosal inflammation in Crohn disease. We tested the hypothesis that supplementary MNs, with or without fish oil (FO), would improve L:M in rural Malawian children aged 1-3 y compared with a control (C) group receiving a placebo. The MNs and FO provided the Recommended Dietary Intake for 26 vitamins, minerals, eicosapentaenoic acid, and docosahexaenoic acid. This was a 3-arm, randomized, double-blind, placebo-controlled clinical trial, with the primary outcomes being the change in L:M (ΔL:M) after 12 and 24 wk of supplementation. Comparisons were made for ΔL:M after 12 and 24 wk within each group by using a Wilcoxon matched pairs signed rank test, because the data are not normally distributed. A total of 230 children had specimens adequate for analysis; all had an abnormal baseline L:M, defined as >0.10. After 12 wk, children who received MNs + FO had a ΔL:M [mean (95% CI)] of -0.10 (-0.04, -0.15; P = 0.001), and children receiving only MNs had ΔL:M of -0.12 (-0.03, -0.21; P = 0.002). After 24 wk, children who received MNs + FO had a ΔL:M of -0.09 (-0.03, -0.15; P = 0.001); children receiving only MNs had a ΔL:M of -0.11 (-0.02, -0.20; P = 0.001), and the C group had ΔL:M of -0.07 (0.02, -0.16); P = 0.002). Linear growth was similar in all groups, ∼4.3 cm over 24 wk. Although the effect was modest, these data suggest MNs can transiently ameliorate EE in rural African children. The trial was registered at clinicaltrials.gov as NCT01593033.

MATERIALI
Numero di prodotto
Marchio
Descrizione del prodotto

Sigma-Aldrich
Retinolo, synthetic, ≥95% (HPLC), (Powder or Powder with Lumps)
Sigma-Aldrich
D-mannitolo, ≥98% (GC)
Sigma-Aldrich
cis-4,7,10,13,16,19-Docosahexaenoic acid, ≥98%
Sigma-Aldrich
Retinolo, BioXtra, ≥97.5% (HPLC), ~3100 U/mg
Supelco
D-mannitolo, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-mannitolo, ACS reagent
Sigma-Aldrich
D-mannitolo, ≥98% (GC), suitable for plant cell culture
USP
Mannitolo, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Retinolo, ≥95.0% (HPLC), ~2700 U/mg
Sigma-Aldrich
Lactulose, ≥98.0% (HPLC)
Sigma-Aldrich
D-mannitolo, BioUltra, ≥99.0% (sum of enantiomers, HPLC)
Sigma-Aldrich
D-mannitolo, meets EP, FCC, USP testing specifications
Supelco
Retinol solution, 100 μg/mL ± 25% (Refer to COA) (Ethanol with 0.1% (w/v) BHT), ampule of 1 mL, reference material, Cerilliant®
Sigma-Aldrich
D-mannitolo, BioXtra, ≥98% (HPLC)
D-mannitolo, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Lactulose, ≥95% (HPLC)
Millipore
D-mannitolo, ACS reagent, suitable for microbiology, ≥99.0%
Supelco
cis-4,7,10,13,16,19-Docosahexaenoic acid, analytical standard
Sigma-Aldrich
D-mannitolo, tested according to Ph. Eur.
USP
Lactulose, United States Pharmacopeia (USP) Reference Standard
Supelco
D-mannitolo, ≥99.9999% (metals basis), for boron determination
Lactulose for peak identification, European Pharmacopoeia (EP) Reference Standard
Lactulose, European Pharmacopoeia (EP) Reference Standard